Valsartan plus hydrochlorothiazide: A review of its use since its introduction

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 12, 2011, Pages 1975-1984

  Bains, Jujhar ^a   Smith, William B ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Fixed dose combination; Hydrochlorothiazide; Hypertension; Valsartan

Indexed keywords

ALCOHOL; AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ATENOLOL; BARBITURIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LITHIUM; LOSARTAN; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; COUGHING; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG COMPETITION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FETOTOXICITY; FOOD; FOOD DRUG INTERACTION; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; KIDNEY DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; RECOMMENDED DRUG DOSE; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; SKULL HYPOPLASIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URIC ACID BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG COMBINATIONS; DRUG COSTS; DRUG SYNERGISM; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RENAL INSUFFICIENCY; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79960439166     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.587124     Document Type: Review

References (82)

1. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38 (Pubitemid 20113741)
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72 (Pubitemid 37430158)
3. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) Statement on Management of Hypertension. J Hypertens 2003;21:1983-92
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000;355:253-9
5. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393-404 (Pubitemid 35469393)
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
7. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206 (Pubitemid 37430058)
8. Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drug 2005;5:171-83 (Pubitemid 40994271)
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62 (Pubitemid 28269185)
10. Ambrosioni E. Healthcare benefits of very-low-dose combination treatment in the management of hypertension. J Hypertens 2001;19:S29-36 (Pubitemid 33753146)
11. Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997;10:306-10S
12. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-56
13. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990;8:565-72 (Pubitemid 20301433)
14. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7
15. Dahlof B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995;9(Suppl 5):S37-44
16. Nio Y, Matsubara H, Murasawa S, et al. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995;95:46-54
17. Unger T, Dahlof B. Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst 2010;11(1):75-7
18. Inada Y, Wada T, Ojima M, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997;19:1079-99 (Pubitemid 27431498)
19. McQueen M, Lonn E, Gerstein HC, et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest Suppl 2005;240:143-56
20. Devereux R, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-62 (Pubitemid 39238023)
21. Thurmann P, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42 (Pubitemid 28512229)
22. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693-704 (Pubitemid 39434842)
23. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75 (Pubitemid 33126822)
24. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-26 (Pubitemid 39456438)
25. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-65 (Pubitemid 36835100)
26. Criscione L, de Gasparo M, Buhlmayer P, et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993;110:761-71 (Pubitemid 23279290)
27. Wellington K, Faulds D. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002;62:1983-2005
28. Latif F, Tandon S, Obeleniene R, et al. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects. J Card Fail 2001;7:265-8 (Pubitemid 32867967)
29. Black H. Bailey, J, Zappe, D, Samuel, R. Valsartan: more than a decade of experience. Drugs 2009;69:2392-414
30. Waldmeier F, Flesch G, Muller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27:59-71 (Pubitemid 27068372)
31. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19:237-44 (Pubitemid 28218418)
32. Novartis. Diovan HCT prescribing information [online. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/diovan-hct.pdf. [Last accessed 1 January 2011]
33. Corea L, Cardoni O, Fogari F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6 (Pubitemid 26354455)
34. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810 (Pubitemid 26397279)
35. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147-51 (Pubitemid 26329294)
36. Calvo C, Hermida RC. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22:837-46 (Pubitemid 38543577)
37. Cifkova R, Peleska J. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998;12:563-7 (Pubitemid 28430227)
38. Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25:2765-80 (Pubitemid 37521249)
39. Sicca D. Pharmacotherapy review: angiotensin receptor antagonists. J Clin Hypertens 2005;7:681-4
40. van Brummelen P, Man in't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980;27:328-36 (Pubitemid 10099119)
41. Tarazi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation 1970;41:709-17
42. Jackson EK. Diuretics. In: Hardman JG, Limbird LE, editors The pharmacological basis of therapeutics. 10th edition. New York, New York: McGraw-Hill; US: 2001. p. 757-88
43. Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999;57:751-5;discussion 756-8
44. Close P. Expert report on the clinical documentation. Co-Diovan 80/12.5 mg film-coated tablets (valsartan/hydrochlorothiazide, CGP 63170). Novartis Pharma AG, Basel, Switzerland; 1997
45. Webb R, Navarrete A. Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR). Am J Hypertens 1998;11:59-65 (Pubitemid 28083153)
46. Scholze J, Probst G, Bertsch K. Valsartan alone and in combination with hydrochlorothiazide in general practice: results from two postmarketing surveillance studies involving 54 928 patients with essential hypertension. Clin Drug Invest 2000;20:1-7 (Pubitemid 30468206)
47. Hall J, Marbury T, Gray J, et al. Long term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Drug Assess 1998;1:281-93
48. Lacourciere Y, Wright J Jr, Samuel R, et al. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit 2009;14:112-20
49. Zappe D, Palmer B, Calhoun D, et al. Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage 1 or stage 2 hypertension. J Hum Hyperten 2010;24:483-91
50. Sowers J, Raij L, Jialal I, et al. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens 2010;28:1761-9
51. Chrysant SG, Wombolt DG, Feliciano N, et al. Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Curr Ther Res 1998;59:762-72 (Pubitemid 28533003)
52. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12:861-6 (Pubitemid 29010276)
53. Hall WD, Montoro R, Littlejohn T, et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest 1998;16:203-10 (Pubitemid 28477070)
54. Pool J, Glazer R. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61-73 (Pubitemid 46414029)
55. Nash D, Crikelair N, Zappe D. Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies. Curr Med Res Opin 2008;24:2617-26
56. Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007;20:807-15 (Pubitemid 46936176)
57. White WB, Calhoun DA, Samuel E, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich) 2008;10:450-8
58. Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group tri-al. Clin Ther 2005;27:1013-21 (Pubitemid 41262459)
59. Mallion J-M, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003;12(Suppl 1):36-43 (Pubitemid 36681971)
60. Cushman W, Duprez D, et al. Home and clinic BP responses in elderly individuals with systolic hypertension during initial treatment with combined angiotensin receptor blocker+diuretic compared to monotherapy. J Hypertens 2010;28(Poster Session 27: Clinical Trials 2):e472-3
61. Izzo J, Weintraub H, et al. Efficacy and tolerability of combined angiotensin receptor blocker+diuretic therapy vs component monotherapies in elderly individuals with systolic hypertension: results from valvet. J Hypertens 2010;28(Poster Session 27: Clinical Trials 2):e475
62. Duprez D, Weintraub H, Samuel R, et al. Effect of valsartan, hydrochlorothiazide, and its combination on 24-hour ambulatory blood pressure response in elderly individuals with systolic hypertension: a valvet substudy. J Hypertens 2010;28(Poster Sesssion 27: Clinical Trials 2):e476
63. Weir MR, Ferdinand KC, Flack JM, et al. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 2005;46:508-13 (Pubitemid 41376830)
64. Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST Study. Clin Ther 2005;27:578-87 (Pubitemid 40835968)
65. Ruilope LM, Heintz D, Brandao AA, et al. 24-hour ambulatory blood-pressure effects of valsartan & hydrochlorothiazide combinations compared with amlodipine in hypertensive pa-tients at increased cardiovascular risk: a VAST sub-study. Blood Press Monit 2005;10:85-91 (Pubitemid 40592697)
66. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31 (Pubitemid 38781102)
67. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004;363:2049-51 (Pubitemid 38781107)
68. Wagstaff A. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs 2006;66:1881-901 (Pubitemid 44596199)
69. Franco RJS, Goldflus S, McQuitty M, et al. Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. Blood Press 2003;12(Suppl 2):41-7 (Pubitemid 38112144)
70. Lacourciere Y, Wright J, Samuel R, et al. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit 2009;14:112-20
71. Everett BM, Glynn RJ, Danielson E, et al. Val-MARC Investigators. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther 2008;30:661-72 (Pubitemid 351680499)
72. Zappe DH, Sowers JR, Hsueh WA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008;10:894-903
73. Hanes DS, Weir MR. Renal protection in chronic kidney disease. In: Oparil S, Weber MA, editors Hypertension. 2nd edition. Elsevier, Inc; Philadelphia, PA: 2005
74. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001;29:270-9 (Pubitemid 32926981)
75. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(Suppl):2-6
76. Jackson KC II, Sheng X, Nelson RE, et al. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008;30:1558-63
77. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19 (Pubitemid 47176510)
78. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
79. Yang W, Chang J, Kahler KH, et al. Compliance and healthcare utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 15-19 May 2010, Atlanta, GA, USA
80. Chang J, Yang W, Fellers T, et al. Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement. Curr Med Res Opin 2010;26:2203-12
81. Chiesa D, Pfiffner D, Meier B, et al. Sexual activity in hypertensive men. J Hum Hypertens 2003;17:515-21 (Pubitemid 36949446)
82. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002;4:202-10